[1]侯秋雨,季晓琳,罗 强,等.原发性肺腺癌组织中巨噬细胞CD68+、CD163+的表达与临床病理学特征及预后相关性研究[J].现代检验医学杂志,2026,41(01):64-69.[doi:10.3969/j.issn.1671-7414.2026.01.013]
　HOU Qiuyu,JI Xiaolin,LUO Qiang,et al.Study on the Correlation between the Expression of CD68+ and CD163+Macrophages in Primary Lung Adenocarcinoma Tissue and Their Clinical Pathological Characteristics and Prognosis[J].Journal of Modern Laboratory Medicine,2026,41(01):64-69.[doi:10.3969/j.issn.1671-7414.2026.01.013]
点击复制

原发性肺腺癌组织中巨噬细胞CD68+、CD163+的表达与临床病理学特征及预后相关性研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第41卷
期数:
2026年01期
页码:
64-69
栏目:
论著
出版日期:
2026-01-15

文章信息/Info

Title:
Study on the Correlation between the Expression of CD68+ and CD163+Macrophages in Primary Lung Adenocarcinoma Tissue and Their Clinical Pathological Characteristics and Prognosis
文章编号:
1671-7414（2026）01-064-06
作者:
侯秋雨a，季晓琳a，罗 强a，张晨策a，齐胜男b，逄格硕a，刘方波a，魏 亮a
青岛市第八人民医院a.心胸外科；b.病理科，山东青岛 266000
Author(s):
HOU Qiuyua，JI Xiaolina，LUO Qianga，ZHANG Chencea，QI Shengnanb，PANG Geshuoa，LIU Fangboa，WEI Lianga
a. Department of Cardiothoracic Surgery; b. Department of Pathology, Qingdao Eighth People’s Hospital, Shandong Qingdao 266000, China
关键词:
原发性肺腺癌; 巨噬细胞; CD68+; CD163+; 病理特征
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2026.01.013
文献标志码:
A
摘要:
目的探究原发性肺腺癌中巨噬细胞分化簇（CD）68+和CD163+的表达与临床病理学特征及预后相关性。方法回顾性收集2018年1月至2019年6月在青岛市第八人民医院胸外科接受外科手术和辅助化疗的106例原发性肺腺癌患者的病理组织及癌旁组织标本，利用免疫组化法检测并比较肺腺癌组织和癌旁组织中CD68+和CD163+表达水平。计算高倍镜下肺腺癌组织和癌旁组织、癌巢和癌巢旁间质的CD68+和CD163+巨噬细胞密度，并依据中位密度区分癌巢/癌巢旁间质CD68+/CD163+高/低密度。随访原发性肺腺癌患者并统计生存期，采用Kaplan-Meier分析癌巢、癌巢旁间质中CD68+和CD163+巨噬细胞密度对原发性肺腺癌患者生存的影响。结果CD68+和CD163+在肺腺癌组织中阳性表达所占比例均高于癌旁组织（χ2=15.881、13.904，均P<0.05）。肺腺癌组织中CD68+和CD163+巨噬细胞密度高于癌旁组织（χ2=44.143、40.070，均P<0.05）。癌巢、癌巢旁间质CD68+高密度组中III~Ⅳ期肺腺癌、T3肿瘤大小、N2~N3期淋巴结所占比例高于CD68+低密度组（χ2=6.788~10.604，均P<0.05）。癌巢、癌巢旁间质CD163+高密度组中III~Ⅳ期肺腺癌、T3肿瘤大小、N2~N3期淋巴结所占比例高于CD163+低密度组（χ2=7.556~17.743，均P<0.05）。癌巢CD68+高密度组的生存率59.32%（35/59）低于癌巢CD68+低密度组的生存率82.98%（39/47）（χ2=7.332，P<0.05）；癌巢旁间质CD68+高密度组的生存率56.36%（31/55）低于癌巢旁间质CD68+低密度组的生存率84.31%（43/51）（χ2=9.518，P<0.05）。癌巢CD163+高密度组的生存率58.93%（33/56）低于癌巢CD163+低密度组的生存率82.00%（41/50）（χ2=7.137，P<0.05）；癌巢旁间质CD163+高密度组的生存率55.56%（30/54）低于癌巢旁间质CD163+低密度组的生存率84.62%（44/52）（χ2=12.487，P<0.05）。结论原发性肺腺癌组织中巨噬细胞CD68+和CD163+的密度较高，癌巢、癌巢旁间质CD68+和CD163+高密度与肺腺癌进展和浸润以及较低的生存率有关。
Abstract:
Objective To investigate the expression of macrophage clusters of differentiation (CD) 68+ and CD163+ in primary lung adenocarcinoma and their correlation with clinical pathological characteristics and prognosis. Methods This study retro-spectively collected pathological tissue and adjacent tissue samples from 106 patients with primary lung adenocarcinoma who un-derwent surgical and adjuvant chemotherapy in the Department of Cardiothoracic Surgery of the Qingdao Eighth People’s Hos-pital from January 2018 to June 2019. Immunohistochemistry was applied to detect and compare the expression levels of CD68+and CD163+ in lung adenocarcinoma tissue and adjacent tissue. Calculated the density of CD68+ and CD163+ macrophages in lung adenocarcinoma tissue andadjacent tissue, cancer nests and adjacent stroma under high magnification, and distinguished high/low density of CD68+/CD163+ in cancer nests/adjacent stroma based on median density. Primary lung adenocarcinoma pa-tients were followed up to measure survival time, and Kaplan-Meier was applied to analyze the impacts of densities of CD68+ and CD163+ macrophages in cancer nests and adjacent stroma on the survival of patients with primary lung adenocarcinoma. Results The proportions of positive expression of CD68+ and CD163+ in lung adenocarcinoma tissues were higher than those in adjacent tissues (χ2=15.881, 13.904, all P<0.05). The densities of CD68+ and CD163+ macrophages in lung adenocarcinoma tissues were higher than those in adjacent tissues (χ2=44.143, 40.070, all P<0.05). The proportions of stage III-IV lung adenocarcinoma, T3 tumor size, and N2~N3 lymph nodes in the cancer nests and adjacent stroma CD68+ high-density groups were higher than those in the CD68+ low-density groups (χ2=6.788~10.604, all P<0.05). The proportions of stage III~IV lung adenocarcinoma, T3 tumor size, and N2~N3 lymph nodes in the cancer nests and adjacent stroma CD163+ high-density groups were higher than those in the CD163+ low-density groups (χ2=7.556~17.743, all P<0.05). The survival rate of high density of cancer nests CD68+ was 59.32% (35/59), which was lower than 82.98% (39/47) of low density of cancer nests CD68+ (χ2=7.332, P<0.05); the survival rate of high density of adjacent stroma CD68+ was 56.36% (31/55), which was lower than 84.31% (43/51) of low density of adjacent stroma CD68+ (χ2=9.518, P<0.05). The survival rate of high density of cancer nests CD163+ was 58.93% (33/56), which was lower than 82.00% (41/50) of low density of cancer nests CD163+(χ2=7.137, P<0.05); the survival rate of high density of adjacent stroma CD163+ was 55.56% (30/54), which was lower than 84.62% (44/52) of low density of adjacent stroma CD163+(χ2=12.487, P<0.05). Conclusions The densities of CD68+and CD163+macrophages are higher in primary lung adenocarcinoma tissues, and the high densities of CD68+ and CD163+ in cancer nests and adjacent stroma are associated with the progression and infiltration of lung adenocarcinoma, as well as a lower survival rate..

参考文献/References:

[1] NOORELDEEN R, BACH H. Current and future development in lung cancer diagnosis[J]. International Journal of Molecular Sciences, 2021, 22(16): 8661.
[2] 田雪琪,宋佳俊,顾怿丰,等.基于血液生物标志物的外周免疫评分及在非小细胞肺癌应用中的研究进展[J].现代检验医学杂志,2024,39(1):192-198. TIAN X Q, SONG J J, GU Y F, et al. Research progress of peripheral immune score based on blood biomarkers and its application in non-small cell lung cancer[J]. Journal of Modern Laboratory Medicine, 2024, 39(1): 192-198.
[3] LARROQUETTE M, GUEGAN J P, BESSE B, et al. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies[J]. Journal for Immunotherapy of Cancer, 2022, 10(5): e003890.
[4] ZHANG J W, LI S W, LIU F K, et al. Role of CD68 in tumor immunity and prognosis prediction in pan-cancer[J]. Scientific Reports, 2022, 12(1): 7844.
[5] 郭益玮,郭荣昌,李萍,等.CD68-TAMs和CD105-MVD在喉鳞状细胞癌组织中的表达及临床意义[J].河北医学,2023,29(3):387-392. GUO Y W, GUO R C, LI P, et al. The expression and clinical significance of CD68-TAMs and CD105-MVD in laryngeal squamous cell carcinoma[J]. Hebei Medicine, 2023, 29(3): 387-392.
[6] 边毅,吕金,张谦,等.癌组织CD163和动力蛋白激活蛋白2表达与皮肤恶性黑色素瘤临床病理特征的关系[J].中华实用诊断与治疗杂志,2021,35(11):1128-1130. BIAN Y, LYU J, ZHANG Q, et al. Correlations of CD163 and DCTN2 with the clinicopathological features of cutaneous malignant melanoma[J]. Journal of Chinese Practical Diagnosis and Therapy, 2021, 35(11): 1128-1130.
[7] D?NIZ C, MORENO C, MAC?A I, et al. Potential impact of omega 6/3 ratio and CD68+ macrophage infiltration on survival in NSCLC patients undergoing pulmonary resection[J]. Current Oncology, 2024, 31(9): 5098-5106.
[8] 国家卫生健康委办公厅.原发性肺癌诊疗指南(2022年版)[J].协和医学杂志,2022,13(4):549-570. General Office of National Health Commission of the People’s Republic of China. Clinical practice guideline for primary lung cancer ( 2022 version)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(4): 549-570.
[9] KADOMOTO S, IZUMI K, MIZOKAMI A. Macrophage polarity and disease control[J]. International Journal of Molecular Sciences, 2021, 23(1): 144.
[10] GAO J, LIANG Y Z, WANG L. Shaping polarization of tumor-associated macrophages in cancer immunotherapy[J]. Frontiers in Immunology, 2022, 13: 888713.
[11] WANG H, TIAN T, ZHANG J H. Tumor-Associated macrophages (TAMs) in colorectal cancer (CRC): from mechanism to therapy and prognosis[J]. International Journal of Molecular Sciences, 2021, 22(16): 8470.
[12] XU R, LEE Y J, KIM C H, et al. Invasive FoxM1 phosphorylated by PLK1 induces the polarization of tumor-associated macrophages to promote immune escape and metastasis, amplified by IFITM1[J]. Journal of Experimental& Clinical Cancer Research, 2023, 42(1): 302.
[13] NETZER C, VON ARPS-AUBERT V, MA?INKOVI?I, et al. Association between spatial distribution of leukocyte subsets and clinical presentation of head and neck squamous cell carcinoma[J]. Frontiers in Immunology, 2024, 14: 1240394.
[14] XU M S, ZHANG T, XIA R L, et al. Targeting the tumor stroma for cancer therapy[J]. Molecular Cancer, 2022, 21(1): 208.
[15] DAVIS J M, CHENG B L, DRAKE M M, et al. Pancreatic stromal Gremlin 1 expression during pancreatic tumorigenesis[J]. Genes & Diseases, 2020, 9(1): 108-115.
[16] DAUNKE T, BECKINGER S, RAHN S, et al. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma[J]. Frontiers in Immunology, 2023, 14: 1157397.
[17] CHOHAN M H, PERRY M, LAURANCE-YOUNG P, et al. Prognostic role of CD68+ and CD163+ Tumour-Associated macrophages and PD-L1 expression in oral squamous cell carcinoma: a meta-analysis[J]. British Journal of Biomedical Science, 2023, 80: 11065.

相似文献/References:

[1]王 婷,张冰云,陈秀慧,等.多发性骨髓瘤患者化疗前后骨髓中巨噬细胞和噬血细胞变化及与临床预后价值的相关性[J].现代检验医学杂志,2025,40(03):150.[doi:10.3969/j.issn.1671-7414.2025.03.028]
　WANG Ting,ZHANG Bingyun,CHEN Xiuhui,et al.Changes of Macrophages and Hemophagocytes in Bone Marrow of Patients with Multiple Myeloma before and after Chemotherapy and Their Correlation with Clinical Prognostic Value[J].Journal of Modern Laboratory Medicine,2025,40(01):150.[doi:10.3969/j.issn.1671-7414.2025.03.028]
[2]安丽伟,韩娇娇,谢阳阳,等.Caspase-8/GSDME通路调控巨噬细胞焦亡在心肌梗死大鼠模型中的机制研究[J].现代检验医学杂志,2025,40(06):165.[doi:10.3969/j.issn.1671-7414.2025.06.030]
　AN Liwei,HAN Jiaojiao,XIE Yangyang,et al.Mechanism of Macrophage Pyroptosis Regulated by Caspase-8/GSDME Pathway in Rat Model of Myocardial Infarction[J].Journal of Modern Laboratory Medicine,2025,40(01):165.[doi:10.3969/j.issn.1671-7414.2025.06.030]
[3]张 伟,蔡振花,杨,等.肿瘤细胞来源外泌体miR-21诱导巨噬细胞焦亡促进胃癌细胞转移机制的实验研究[J].现代检验医学杂志,2026,41(01):29.[doi:10.3969/j.issn.1671-7414.2026.01.007]
　ZHANG Wei1a,CAI Zhenhua1b,YANG Chen1c,et al.Experimental Study on the Mechanism of Tumor Cell-Derived Exosomes miR-21 Inducing Macrophage Pyroptosis to Promote Metastasis in Gastric Cancer Cells[J].Journal of Modern Laboratory Medicine,2026,41(01):29.[doi:10.3969/j.issn.1671-7414.2026.01.007]

备注/Memo

备注/Memo:
基金项目：青岛市医药卫生科研指导项目（编号：2023-wjzd086）。
作者简介：侯秋雨（1971-），男，硕士，主任医师，研究方向：普胸外科，E-mail：zx0839@sina.com。
通讯作者：魏亮（1983-），男，硕士，主治医师，研究方向：普胸外科，E-mail：weiliang0928@126.com。
更新日期/Last Update: 2026-01-15